Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future
Y Zhang, H Chen, R Li, K Sterling… - Signal transduction and …, 2023 - nature.com
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …
The neuroimmune axis of Alzheimer's disease
Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder with
multifaceted neuropathological features, including β-amyloid plaques, neurofibrillary …
multifaceted neuropathological features, including β-amyloid plaques, neurofibrillary …
The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation
Objective This study is to investigate the role of gut dysbiosis in triggering inflammation in
the brain and its contribution to Alzheimer's disease (AD) pathogenesis. Design We …
the brain and its contribution to Alzheimer's disease (AD) pathogenesis. Design We …
Alzheimer's disease: an updated overview of its genetics
J Andrade-Guerrero, A Santiago-Balmaseda… - International journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is the most common neurodegenerative disease in the world. It is
classified as familial and sporadic. The dominant familial or autosomal presentation …
classified as familial and sporadic. The dominant familial or autosomal presentation …
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …
dependent dementia. There is currently no effective treatment for AD, which may be …
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
BAH Smith, CR Bertozzi - Nature reviews Drug discovery, 2021 - nature.com
Carbohydrates—namely glycans—decorate every cell in the human body and most secreted
proteins. Advances in genomics, glycoproteomics and tools from chemical biology have …
proteins. Advances in genomics, glycoproteomics and tools from chemical biology have …
Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease
Communication within the glial cell ecosystem is essential for neuronal and brain health,–.
The influence of glial cells on the accumulation and clearance of β-amyloid (Aβ) and …
The influence of glial cells on the accumulation and clearance of β-amyloid (Aβ) and …
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease
Glia have been implicated in Alzheimer's disease (AD) pathogenesis. Variants of the
microglia receptor triggering receptor expressed on myeloid cells 2 (TREM2) increase AD …
microglia receptor triggering receptor expressed on myeloid cells 2 (TREM2) increase AD …
Human monocyte subsets and phenotypes in major chronic inflammatory diseases
Human monocytes are divided in three major populations; classical (CD14+ CD16−), non-
classical (CD14dimCD16+), and intermediate (CD14+ CD16+). Each of these subsets is …
classical (CD14dimCD16+), and intermediate (CD14+ CD16+). Each of these subsets is …